

## General Information

Name: Prof. Dr. med. Christian Buske  
Date of Birth: 26.08.1965  
Gender: Male  
Address: Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm, James-Franck-Ring (N27), 89081 Ulm, Germany  
Phone: +49 731 50 65801  
E-Mail: [christian.buske@uni-ulm.de](mailto:christian.buske@uni-ulm.de)  
Current Position: Medical Director, Institute of Experimental Cancer Research, Ulm University

## Academic Education

1993 Thesis in Medicine (Hematology/Oncology) (Dr. med.)  
1985-1992 Medical Study, Westfälische-Wilhelms-Universität, Münster

## Academic Degrees

2009 Professorship, Ulm University, Germany  
1993 MD, University of Münster, Germany

## Professional Experience

Since 2009 Medical Director – Institute of Experimental Cancer Research, Ulm University; Attending Physician, Department of Internal Medicine III, Ulm University Hospital  
2004-2009 Attending Physician Med. Clinic III, Klinikum Großhadern, Munich  
2003 Venia legendi for Internal Medicine (Habilitation)  
2003 Consultant in Internal Medicine  
2001-2004 Postdoctoral Fellowship Med. Clinic III, Klinikum Großhadern, Munich  
1998-2001 Postdoctoral Fellow, British Columbia Cancer Agency (BCCA), Vancouver, Canada  
1992-1997 Medical Fellowship Med. Klinik, Georg-August-Universität, Göttingen

## Miscellaneous

### Honors and Awards

2000 Canadian Research Award 2000  
2000 First Prize Young Investigator Award: 29<sup>st</sup> Annual Meeting of the International Society for Experimental Hematology (ISEH)  
1998-2000 Postdoctoral fellowship of German Research Council (DFG)  
1987-1992 Stipend, Studienstiftung des Deutschen Volkes

### Membership in advisory boards

Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)  
Deutsche Gesellschaft für Innere Medizin (DGIM)  
American Society of Hematology (ASH)  
International Society for Hematology and Stem Cells (ISEH)  
European Society for Medical Oncology (ESMO)

### Editorial boards

Leukemia, Experimental Hematology

### Reviewer Journals

Science, N Engl J Med, Cancer Cell, Cell Stem Cell, J Clin Invest, Blood, Cancer Research, Oncology

### Fundings

DFG, Deutsche Krebshilfe, BMBF, Else-Kröner-Fresenius-Stiftung, Wilhelm Sander-Stiftung

### Committees

President, German Lymphoma Alliance e.V. (GLA e.V.)  
Coordinator, 'European Consortium for Waldenström's Macroglobulinemia' (ECWM)  
Coordinator, 'German National Marginal Zone Lymphoma Registry'  
Chair, ESMO Working Party on Hematological Neoplasms  
Chair, DGHO Clinical Guidelines on indolent B – NHL

### **Publications**

1. Feder K, Edmaier-Schröger K, Rawat V, Kirsten N, Metzeler K, Kraus J, Döhner K, Döhner H, Kestler H, Feuring-Buske M, Buske C. Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis. **Leukemia**. 2019 Nov 22. [Epub ahead of print]
2. Cusan M, Vegi N, Mulaw M, Bamezai S, Kaiser L, Deshpande A, Greif P, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries K, Armstrong S, Hiddemann W, Feuring-Buske M, Buske C. Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus. **Blood**. 2017;129(3):319-23.
3. Ng S, Mitchell A, Kennedy J, Chen W, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer A, Schuh A, Yee K, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel W, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk P, Zandstra P, Minden M, Dick J, Wang J. A 17-gene stemness score for rapid determination of risk in acute leukaemia. **Nature**. 2016;540(7633):433-37.
4. Vegi N, Klappacher J, Oswald F, Mulaw M, Mandoli A, Thiel V, Bamezai S, Feder K, Martens J, Rawat V, Mandal T, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Stunnenberg H, Feuring-Buske M, Buske C. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML. **Cell Rep**. 2016;16(2):498-507
5. Edmaier K, Stahnke K, Vegi N, Mulaw M, Ihme S, Scheffold A, Rudolph K, Buske C. Expression of the lymphoid enhancer factor 1 is required for normal hematopoietic stem and progenitor cell function. **Leukemia**. 2014;28(1):227-30.
6. Metzeler K, Heilmeier B, Edmaier K, Rawat V, Dufour A, Döhner K, Feuring-Buske M, Braess J, Spiekermann K, Buchner T, Sauerland M, Döhner H, Hiddemann W, Bohlander S, Schlenk R, Bullinger L, Buske C. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. **Blood**. 2012;120(10):2118-26.
7. Eppert K, Takenaka K, Lechman E, Waldron L, Nilsson B, van Galen P, Metzeler K, Poepl A, Ling V, Beyene J, Canty A, Danska J, Bohlander S, Buske C, Minden M, Golub T, Jurisica I, Ebert B, Dick J. Stem cell gene expression programs influence clinical outcome in human leukemia. **Nat Med**. 2011;17(9):1086-93.
8. Rawat V, Arseni N, Ahmed F, Mulaw M, Thoene S, Heilmeier B, Sadlon T, D'Andrea R, Hiddemann W, Bohlander S, Buske C, Feuring-Buske M. The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. **Proc Natl Acad Sci U S A**. 2010;107(39):16946-51.
9. Petropoulos K, Arseni N, Schessl C, Stadler C, Rawat V, Deshpande A, Heilmeier B, Hiddemann W, Quintanilla-Martinez L, Bohlander S, Feuring-Buske M, Buske C. A novel role for Lef-1 as a central transcription mediator of Wnt signalling in leukemogenesis. **J Exp Med**. 2008;197(205):515-22.
10. Deshpande A, Cusan M, Rawat V, Reuter H, Krause A, Pott C, Quintanilla-Martinez L, Kakadia P, Kuchenbauer F, Ahmed F, Delabesse E, Hahn M, Lichter P, Kneba M, Hiddemann W, Macintyre E, Mecucci C, Ludwig W, Humphries R, Bohlander S, Feuring-Buske M, Buske C. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. **Cancer Cell**. 2006;10(5):363-74.